Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients

Abstract

The aim of this study was to determine whether or not statins influence biochemical recurrence (BCR) in Korean patients undergoing surgical treatment for prostate cancer. We reviewed data from 687 men who underwent radical retropubic prostatectomy and who did not receive neoadjuvant treatment. Of these patients, 87 reported the use of preoperative statins at surgery. BCR-free survival was determined after exclusion of 78 patients with lymph node metastases and/or who received immediate adjuvant treatment. Patients on statin therapy were more likely to have a co-morbid disease (Po0.05). Mean PSA (9.6 vs 13.6 ng ml À1, P ¼ 0.002) and PSA density (0.27 vs 0.38 ng ml À1 ml À1, Po0.001) were significantly lower in patients on statins. However, in the multivariable linear regression model, statin use was not associated with a decrease in PSA. Overall BCR for the entire cohort was not significantly different between the statin and nonstatin groups. On multivariate analysis, positive surgical margin and seminal vesicle invasion were independent risk factors for BCR-free survival, whereas other variables, including statin use, were not significant in predicting the risk of BCR. Patients with positive surgical margin and seminal vesicle invasion had a 2.1-(odds ratio, 2.15; 95% confidence interval, 1.29-3.57; P ¼ 0.003) and 2.2-fold risk (odds ratio, 2.21; 95% confidence interval, 1.25-3.89; P ¼ 0.006) of BCR. Preoperative statin use is not associated with reduced BCR following radical prostatectomy.

Pathological Characteristics, Biochemical Recurrence and Functional Outcome in Radical Prostatectomy Patients on Statin Therapy

“…Two papers reported more favorable pathologic characteristics [20,21]. Only one study found a dose-dependent reduction of the biochemical recurrence risk [22], while three others reported that there was no statistically significant association [11,20,23]. Ritch et al [24] had similar findings as our series.…”

Preoperative Statin Therapy is not Associated with Biochemical Recurrence After Radical Prostatectomy: Our Experience and Meta-Analysis

“…22 We also excluded studies of statin use and PrCa recurrence in men who received another treatment option, eg radiation and/or hormones, or those that analyzed BCR and PrCa specific mortality together. 23,24 In the metaanalysis we included 5 studies that captured BCR in relation to statin use [12][13][14][15][16] as well as the results of the current study.…”

“…11 Several groups have assessed the impact of statins on the BCR risk after ORRP and reported inconsistent findings. [12][13][14][15][16] The primary objective of the current study was to evaluate the effect of statin therapy on BCR in a large cohort of men who underwent ORRP, as done by a single surgeon, of whom all participated in a long-term prospective, longitudinal study. A second objective was to perform a meta-analysis of the effect of statins on BCR after ORRP using data from our institution and 5 peer reviewed, published studies.…”

Prostate Cancer Risk in Men with Baseline History of Coronary Artery Disease: Results from the REDUCE Study

“…Prior studies suggest elevated serum cholesterol, a known CAD risk factor, may be associated with PCa risk and disease grade (4,5). Furthermore, several recent studies found statins, which benefit men with CAD, may reduce overall PCa risk and disease recurrence (6,7), though conflicting data exist (8). Only a few studies examined the relationship between CAD and PCa risk with mixed results (9)(10)(11)(12)(13).…”